➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Medtronic
McKinsey
Dow
Moodys

Last Updated: May 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for LY3039478

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug LY3039478?

LY3039478 is an investigational drug.

There have been 8 clinical trials for LY3039478. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Neoplasms, and Multiple Myeloma. The leading clinical trial sponsors are Eli Lilly and Company, National Cancer Institute (NCI), and Fred Hutchinson Cancer Research Center.

There are eleven US patents protecting this investigational drug and one hundred and thirty-four international patents.

Recent Clinical Trials for LY3039478
TitleSponsorPhase
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple MyelomaNational Cancer Institute (NCI)Phase 1
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple MyelomaFred Hutchinson Cancer Research CenterPhase 1
A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1

See all LY3039478 clinical trials

Clinical Trial Summary for LY3039478

Top disease conditions for LY3039478
Top clinical trial sponsors for LY3039478

See all LY3039478 clinical trials

US Patents for LY3039478

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY3039478   Get Started for $10 Combinations of LSD1 inhibitors for use in the treatment of solid tumors Oryzon Genomics, S.A. (Madrid, ES)   Get Started for $10
LY3039478   Get Started for $10 Chemical reprogramming of human glial cells into neurons for brain and spinal cord repair The Penn State Research Foundation (University Park, PA)   Get Started for $10
LY3039478   Get Started for $10 Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof RACE ONCOLOGY LTD. (Melbourne, AU)   Get Started for $10
LY3039478   Get Started for $10 Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof RACE ONCOLOGY LTD. (Melbourne, AU)   Get Started for $10
LY3039478   Get Started for $10 Targeted treatment of leiomyosarcoma ELI LILLY AND COMPANY (Indianapolis, IN)   Get Started for $10
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for LY3039478

Drugname Country Document Number Estimated Expiration Related US Patent
LY3039478 Argentina AR107871 2036-03-15   Get Started for $10
LY3039478 Australia AU2017233898 2036-03-15   Get Started for $10
LY3039478 Brazil BR112018068565 2036-03-15   Get Started for $10
LY3039478 Canada CA3017411 2036-03-15   Get Started for $10
LY3039478 China CN109195593 2036-03-15   Get Started for $10
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Colorcon
Boehringer Ingelheim
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.